Detalhe da pesquisa
1.
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.
N Engl J Med
; 389(20): 1839-1850, 2023 Nov 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37870973
2.
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.
N Engl J Med
; 389(22): 2039-2051, 2023 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37870976
3.
SIRPG expression positively associates with an inflamed tumor microenvironment and response to PD-1 blockade.
Cancer Immunol Immunother
; 73(8): 147, 2024 Jun 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38833156
4.
Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study.
Cancer Immunol Immunother
; 73(7): 124, 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38727837
5.
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer.
BMC Med
; 22(1): 174, 2024 Apr 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38658988
6.
Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis.
BMC Cancer
; 24(1): 186, 2024 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38331773
7.
Special issue "The advance of solid tumor research in China": FGFR4 alterations predict efficacy of immune checkpoint inhibitors in nonsmall cell lung cancer.
Int J Cancer
; 152(1): 79-89, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36062503
8.
KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC.
Int J Cancer
; 153(3): 623-634, 2023 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37141294
9.
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
N Engl J Med
; 382(1): 41-50, 2020 01 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31751012
10.
Clinical activity of pembrolizumab with or without chemotherapy in advanced pulmonary large-cell and large-cell neuroendocrine carcinomas: a multicenter retrospective cohort study.
BMC Cancer
; 23(1): 443, 2023 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37189075
11.
TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC.
Future Oncol
; 19(21): 1461-1472, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37249038
12.
TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors.
Future Oncol
; 19(2): 123-135, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36877099
13.
Prognostic value of inflammatory and nutritional indexes among advanced NSCLC patients receiving PD-1 inhibitor therapy.
Clin Exp Pharmacol Physiol
; 50(2): 178-190, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36419356
14.
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.
Lancet Oncol
; 23(2): 220-233, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35038432
15.
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 23(6): 739-747, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35576956
16.
On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial.
Mol Cancer
; 21(1): 4, 2022 01 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34980131
17.
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
Lancet
; 398(10308): 1344-1357, 2021 10 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34555333
18.
Selpercatinib or Chemotherapy in RET Fusion-Positive NSCLC. Reply.
N Engl J Med
; 390(4): 381-382, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38265654
19.
VTE with Amivantamab plus Chemotherapy in NSCLC. Reply.
N Engl J Med
; 390(6): 579-580, 2024 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38324503
20.
ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC.
Cancer Immunol Immunother
; 71(1): 219-228, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34097116